Gene Screen: Computational Biologist Aarathi Sugathan Uses Genetic Insights to Fuel Drug Discoveries
Senior Scientist of Computational Biologis Aarathi Sugathan uses genetic insights to identify and create actionable therapeutic targets for patients.
Read More
Postdoc Opportunities at 23andMe
If you’re a recent Ph.D. graduate interested in opportunities to work with genetic data in the search for new insights into human disease and new treatments for those conditions, then...
Read More
23andMe Launches Sarcoidosis Study
Diseases are considered rare if they affect fewer than 200,000 in the United States, but collectively rare diseases — there are nearly 7,000 — are more common than we realize,...
Read More
23andMe’s Drug Discovery Process Explained
23andMe's vice president for human genetics, Adam Auton, explains how our unique database shapes our approach to drug discovery. It begins with human genetics, but it doesn't end there.
Read More
Patients Inspire Therapeutics Scientist
Both a physician and a scientist, John Mathews, a senior clinical development fellow on 23andMe’s Therapeutics team, said he is inspired by patients in the work he does, working where medicine and scientific discovery converge.
Read More
Tackling Tough Problems with the 23andMe Therapeutics Team
Kipper Fletez-Brant, a computational biologist with our Therapeutics division, thought he’d be a physicist one day.Growing up in Phoenix, Arizona, Kipper escaped the heat reading “hard-sci-fi novels” with mind-bending plots...
Read More
Helping to Drive Discovery in 23andMe’s Therapeutics Division
Xin Fang’s interest in science started at the dinner table, listening to her parents talking about what they did each day. Both her mom and dad are plant scientists. Her mom...
Read More
Talking About Rare Disease with Senior Scientist Suyash Shringarpure
23andMe senior scientist in statistical genetics, Suyash Shringarpure, Ph.D. talks about 23andMe's research model and how it offers a surprising opportunity in the study of rare diseases.
Read More
23andMe and GSK Begin First Clinical Trial with Cancer Therapy
A drug to fight cancer will be the first potential therapy to emerge from 23andMe and GlaxoSmithKline collaboration as the two companies announced that the new therapy will begin clinical trials.
Read More
Meet 23andMe’s Head of Therapeutics Kenneth Hillan
23andMe's Head of Therapeutics Kenneth Hillan, M.B., Ch.B., discussed his career and the vision for 23andMe's work in therapeutics
Read More